Could a 3-Step immune therapy save Insulin-Making cells in newly diagnosed type 1 diabetes?

NCT ID NCT07610213

Not yet recruiting Disease control Sponsor: Abdullah Kars Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a three-step immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months). The goal is to preserve the body's remaining insulin production by calming the immune attack and teaching the immune system to tolerate insulin. Sixty adults aged 18-45 will receive either the MATIN-2 protocol or standard care, with safety and insulin production monitored for two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DIABETES TYPE 1 DIABETES MELLITUS TYPE 1 DIABETES MELLITUS (T1DM)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kara Harp Okulu (Turkish Military Academy)

Ankara, Ankara, 06000, Turkey (Türkiye)

Contact Email: •••••@•••••